Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Neuroendocrine Tumors 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoid Tumor 1

Interventions

Cisplatin 150Radiotherapy 121Cetuximab 96Docetaxel 60Fluorouracil 56Paclitaxel 45Radiotherapy, Intensity-Modulated 41Carboplatin 40pembrolizumab 34Surveys and Questionnaires 22Erlotinib Hydrochloride 19Nivolumab 18Immunohistochemistry 16Gefitinib 16Drug Therapy 16Gemcitabine 14Pemetrexed 13Gene Expression Profiling 13durvalumab 12Chemotherapy, Adjuvant 12Radiation 11Filgrastim 11Bevacizumab 11Surgical Procedures, Operative 10Polymerase Chain Reaction 10Amifostine 10Celecoxib 9Capecitabine 9Standard of Care 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Head and Neck Neoplasms × fosbretabulin × Clear all
NCT00060242 2010-06-11

Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
EndocrineHead & Neck

Head and Neck Neoplasms, Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡